(Q34659096)

3 August 2017

1 reference

title

Antipsychotic drugs for first-episode schizophrenia: a comparative review (English)

1 reference

3 August 2017

0 references

3

Jeffrey A Lieberman

1 reference

3 August 2017

Kayvon Salimi

1

1 reference

3 August 2017

L Fredrik Jarskog

series ordinal

2

1 reference

3 August 2017

publication date

1 October 2009

1 reference

3 August 2017

1 reference

3 August 2017

volume

23

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

837-855

1 reference

https://scigraph.springernature.com/pub.10.2165/11314280-000000000-00000

3 August 2017

exact match

0 references

cites work

Modeling the early course of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

A selective review of recent North American long-term followup studies of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Neuroleptics and the Natural Course of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Neuropsychological risk indicators for schizophrenia: a review of family studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Meta-analysis of regional brain volumes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Structural abnormalities in deficit and nondeficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11314280-000000000-00000

Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine

21 January 2018

1 reference

12 December 2020

Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients

1 reference

12 December 2020

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

1 reference

12 December 2020

Neuroleptic treatment and caudate plasticity

1 reference

12 December 2020

Another view of therapy for cognition in schizophrenia.

1 reference

12 December 2020

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

1 reference

12 December 2020

Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.

1 reference

12 December 2020

Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals

1 reference

12 December 2020

Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Persistent negative symptoms in schizophrenia: an overview

1 reference

12 December 2020

The deficit state in first-episode schizophrenia

1 reference

12 December 2020

New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol

1 reference

12 December 2020

The McLean–Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis

1 reference

12 December 2020

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

1 reference

12 December 2020

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

12 December 2020

Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs

1 reference

12 December 2020

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

12 December 2020

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

1 reference

12 December 2020

Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.

1 reference

12 December 2020

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

12 December 2020

Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.

1 reference

12 December 2020

Cognitive functioning in first-episode schizophrenia

1 reference

12 December 2020

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

12 December 2020

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

12 December 2020

Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.

1 reference

12 December 2020

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

12 December 2020

Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data.

1 reference

12 December 2020

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

1 reference

12 December 2020

A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia.

1 reference

12 December 2020

Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.

1 reference

12 December 2020

Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study.

1 reference

12 December 2020

Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia.

1 reference

12 December 2020

Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic.

1 reference

12 December 2020

Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study.

1 reference

12 December 2020

A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.

1 reference

12 December 2020

A review of MRI findings in schizophrenia

1 reference

12 December 2020

Antipsychotic drug effects on brain morphology in first-episode psychosis

1 reference

12 December 2020

Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

1 reference

12 December 2020

Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages

1 reference

12 December 2020

Causes and consequences of duration of untreated psychosis in schizophrenia

1 reference

12 December 2020

Delayed detection of psychosis: causes, consequences, and effect on public health

1 reference

12 December 2020

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

12 December 2020

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Antipsychotic medications: metabolic and cardiovascular risk

1 reference

12 December 2020

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial

1 reference

12 December 2020

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

12 December 2020

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

1 reference

12 December 2020

Effect of chronic olanzapine treatment on striatal synaptic organization

1 reference

12 December 2020

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode.

1 reference

12 December 2020

Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.

1 reference

12 December 2020

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

12 December 2020

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

12 December 2020

Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood.

1 reference

12 December 2020

Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia

1 reference

12 December 2020

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

12 December 2020

The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics.

1 reference

12 December 2020

Striatal enlargement in rats chronically treated with neuroleptic.

1 reference

12 December 2020

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

12 December 2020

Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

12 December 2020

Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review

1 reference

12 December 2020

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol

1 reference

12 December 2020

Longitudinal study of brain morphology in first episode schizophrenia

1 reference

12 December 2020

Brain volume changes in the first year of illness and 5-year outcome of schizophrenia.

1 reference

12 December 2020

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

12 December 2020

Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance.

1 reference

12 December 2020

Changes in caudate volume with neuroleptic treatment

1 reference

12 December 2020

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

1 reference

12 December 2020

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.

1 reference

12 December 2020

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

12 December 2020

10.2165/11314280-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1030790319

0 references

1 reference